Clinical trials: Heart Failure With Preserved Ejection Fraction (HFPEF)
Diabetes Mellitus, Heart Failure
Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction
The purpose of this study is to evaluate the results of 99mTc maraciclatide scintigraphy in diabetic subjects with HFPEF. A maximum of 20 subjects with Diabetes Mellitus (DM) and Heart Failure With Preserved Left Ventricular…
- Trial name
- NCT01440517
- Testing
- Tc99m-Maraciclatide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection…
- Trial name
- NCT03448406
- Testing
- Empagliflozin
- Where
- 108 sites in United States, Australia and 9 more
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
Heart Failure With Preserved Ejection Fraction (HFpEF)
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction…
- Trial name
- NCT03877224
- Testing
- Dapagliflozin
- Where
- 101 sites in United States, Argentina and 10 more
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.
Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Global Prevalence of ATTR-CM in Participants With HFpEF
This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with heart failure with preserved…
- Trial name
- NCT04424914
- Testing
- Scintigraphy
- Where
- 51 sites in United States, Canada and 6 more
- Volunteers
- 347 people
- Sponsor
- Pfizer
Heart Failure, Diastolic, Pulmonary Hypertension
Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Aim of the study is to investigate whether Sildenafil treatment results in a reduction of pulmonary artery pressure without decrease of cardiac output (CO) and in improvement of exercise capacity in patients with heart failure…
- Trial name
- NCT01726049
- Testing
- Sildenafil
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- University Medical Center Groningen
Heart Failure With Preserved Ejection Fraction
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
The clinical benefits of the dual Sodium-Glucose cotransporter (SGLT) 1 and 2-inhibition have recently been reported in two clinical trials.
- Trial name
- NCT05562063
- Testing
- Sotagliflozin
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Juan Badimon
Heart Failure With Preserved Ejection Fraction
Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
To determine biomarker responses to Entresto™in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.
- Trial name
- CNEPi (NCT03506412)
- Testing
- Entresto™ 49Mg-51 mg tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Heart Failure With Normal Ejection Fraction, Sleep Apnea
Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep…
- Trial name
- CAT-PEF (NCT03195660)
- Testing
- ASV Therapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 6 people
- Sponsor
- ResMed
Heart Failure
REALIsM-HF Pilot Study
The study aims to explore two marketed devices providing a multimarker monitoring including physical activity under real-life conditions in patients with heart failure with preserved ejection fraction (HFpEF) and with heart…
- Trial name
- REALIsM-HF (NCT03507439)
- Testing
- AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 27 people
- Sponsor
- Bayer
Pulmonary Hypertension Secondary, Heart Failure
Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
The main objective of this study is to determine the clinical efficacy of oral inorganic nitrite verses placebo and the therapeutic response with regards to exercise tolerance in patients with pulmonary hypertension and heart…
- Trial name
- PH-HFpEF (NCT03015402)
- Testing
- Sodium Nitrite
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pittsburgh
Heart Failure With Preserved Ejection Fraction
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF…
- Trial name
- PARALLAX (NCT03066804)
- Testing
- sacubitril/valsartan, Enalapril, Valsartan
- Where
- 380 sites in United States, Argentina and 30 more
- Volunteers
- 2,572 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
- Conditions
- Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Trial name
- NCT03624010
- Testing
- Levosimendan
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tenax Therapeutics, Inc.
Heart Failure With Preserved Ejection Fraction
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition…
- Trial name
- DELIVER (NCT03619213)
- Testing
- Dapagliflozin
- Where
- 348 sites in United States, Argentina and 18 more
- Volunteers
- 6,263 people
- Sponsor
- AstraZeneca
Heart Failure With Normal Ejection Fraction
Treatment of HFpEF With Nitrate Supplement
The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for…
- Trial name
- NCT03289481
- Testing
- Active lozenge
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- MaineHealth
Heart Failure, Heart Failure, Diastolic
Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF
In this study, we will test the feasibility of N-of-1 trials for deprescribing beta-blockers in patients with Heart Failure with Preserved Ejection Fraction.
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure
- Trial name
- NCT04757584
- Testing
- Beta blockers
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Weill Medical College of Cornell University
Heart Failure
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
- Trial name
- NCT03611153
- Testing
- AZD4831 Oral Myeloperoxidase Inhibitor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction
Dapagliflozin (DAPA) Effects in HFpEF
The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure/preserved ejection fraction (HFpEF) and…
- Trial name
- NCT04730947
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Heart Failure
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries.
- Trial name
- SATELLITE (NCT03756285)
- Testing
- AZD4831
- Where
- 13 sites in United States, Denmark and 3 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca